These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention: a single-center experience. Sheikh IR; Ahmed SH; Mori N; Gupta A; Mewissen M; Allaqaband S; Bajwa T JACC Cardiovasc Interv; 2009 Sep; 2(9):871-6. PubMed ID: 19778776 [TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ; J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155 [TBL] [Abstract][Full Text] [Related]
8. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ; JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903 [TBL] [Abstract][Full Text] [Related]
9. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. Allie DE; Hebert CJ; Lirtzman MD; Wyatt CH; Keller VA; Khan MH; Khan MA; Fail PS; Vivekananthan K; Allie SE; Mitran EV; Chaisson G; Stagg SJ; Allie AA; McElderry MW; Barker EA; Walker CM J Invasive Cardiol; 2005 Aug; 17(8):427-32. PubMed ID: 16079449 [TBL] [Abstract][Full Text] [Related]
10. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331 [TBL] [Abstract][Full Text] [Related]
11. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Pinnow E; Gebreeyesus A; Aggrey G; Pichard AD; Satler LF; Kent KM; Lindsay J; Waksman R Cardiovasc Radiat Med; 2004; 5(2):64-70. PubMed ID: 15464942 [TBL] [Abstract][Full Text] [Related]
12. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ; J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319 [TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Chew DP; Lincoff AM; Gurm H; Wolski K; Cohen DJ; Henry T; Feit F; Topol EJ; Am J Cardiol; 2005 Mar; 95(5):581-5. PubMed ID: 15721095 [TBL] [Abstract][Full Text] [Related]
14. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428 [TBL] [Abstract][Full Text] [Related]
16. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Lincoff AM; Bittl JA; Kleiman NS; Sarembock IJ; Jackman JD; Mehta S; Tannenbaum MA; Niederman AL; Bachinsky WB; Tift-Mann J; Parker HG; Kereiakes DJ; Harrington RA; Feit F; Maierson ES; Chew DP; Topol EJ; Am J Cardiol; 2004 May; 93(9):1092-6. PubMed ID: 15110198 [TBL] [Abstract][Full Text] [Related]
17. Bivalirudin for patients with acute coronary syndromes. Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM; N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice. Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342 [TBL] [Abstract][Full Text] [Related]
20. In-hospital safety and effectiveness of bivalirudin in percutaneous peripheral interventions: data from a real-world registry. Shammas NW; Shammas GA; Jerin M; Dippel EJ; Shammas AN J Endovasc Ther; 2010 Feb; 17(1):31-6. PubMed ID: 20199263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]